Huigen Clémence M C, Coukos Alexander, Latifyan Sofiya, Nicod Lalonde Marie, Schaefer Niklaus, Abler Daniel, Depeursinge Adrien, Prior John O, Fraga Montserrat, Jreige Mario
Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
Department of Gastroenterology and Hepatology, Lausanne University Hospital, Lausanne, Switzerland.
EJNMMI Rep. 2025 Aug 4;9(1):27. doi: 10.1186/s41824-025-00258-4.
In the last decade, immunotherapy, particularly immune checkpoint inhibitors, has revolutionized cancer treatment and improved prognosis. However, severe checkpoint inhibitor-induced liver injury (CHILI), which can lead to treatment discontinuation or death, occurs in up to 18% of the patients. The aim of this study is to evaluate the value of PET/CT radiomics analysis for the detection of CHILI.
Patients with CHILI grade 2 or higher who underwent liver function tests and liver biopsy were retrospectively included. Minors, patients with cognitive impairments, and patients with viral infections were excluded from the study. The patients' liver and spleen were contoured on the anonymized PET/CT imaging data, followed by radiomics feature extraction. Principal component analysis (PCA) and Bonferroni corrections were used for statistical analysis and exploration of radiomics features related to CHILI.
Sixteen patients were included and 110 radiomics features were extracted from PET images. Liver PCA-5 showed significance as well as one associated feature but did not remain significant after Bonferroni correction. Spleen PCA-5 differed significantly between CHILI and non-CHILI patients even after Bonferroni correction, possibly linked to the higher metabolic function of the spleen in autoimmune diseases due to the recruitment of immune cells.
This pilot study identified statistically significant differences in PET-derived radiomics features of the spleen and observable changes in the liver on PET/CT scans before and after the onset of CHILI. Identifying these features could aid in diagnosing or predicting CHILI, potentially enabling personalized treatment. Larger multicenter prospective studies are needed to confirm these findings and develop automated detection methods.
在过去十年中,免疫疗法,尤其是免疫检查点抑制剂,彻底改变了癌症治疗方式并改善了预后。然而,严重的检查点抑制剂诱导的肝损伤(CHILI)可导致治疗中断或死亡,高达18%的患者会出现这种情况。本研究的目的是评估PET/CT放射组学分析在检测CHILI中的价值。
回顾性纳入接受肝功能检查和肝活检的2级及以上CHILI患者。未成年人、认知障碍患者和病毒感染患者被排除在研究之外。在匿名的PET/CT成像数据上勾勒出患者的肝脏和脾脏轮廓,然后进行放射组学特征提取。主成分分析(PCA)和Bonferroni校正用于统计分析和探索与CHILI相关的放射组学特征。
纳入16例患者,从PET图像中提取了110个放射组学特征。肝脏PCA-5显示出显著性以及一个相关特征,但在Bonferroni校正后不再显著。即使在Bonferroni校正后,CHILI患者和非CHILI患者的脾脏PCA-5也存在显著差异,这可能与自身免疫性疾病中由于免疫细胞募集导致脾脏代谢功能较高有关。
这项初步研究发现,CHILI发作前后PET/CT扫描中脾脏的PET衍生放射组学特征存在统计学显著差异,肝脏也有可观察到的变化。识别这些特征有助于诊断或预测CHILI,可能实现个性化治疗。需要更大规模的多中心前瞻性研究来证实这些发现并开发自动检测方法。